Tenaya Therapeutics (TNYA) Accumulated Depreciation (2020 - 2026)

Tenaya Therapeutics' Accumulated Depreciation history runs 7 years deep, the most recent figure standing at $41.7 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 19.3% year-over-year to $41.7 million; the TTM figure through Mar 2026 stood at $41.7 million (up 19.3% YoY), while the FY2025 annual figure was $39.9 million, up 23.67% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $41.7 million, up from $39.9 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $41.7 million in Q1 2026, with the low at $10.4 million in Q1 2022.
• The 5-year median for Accumulated Depreciation is $26.5 million (2024), against an average of $26.2 million.
• The sharpest annual moves came in 2023 and 2026: Accumulated Depreciation surged 74.09% in 2023, then gained 19.3% in 2026.
• Tenaya Therapeutics' Accumulated Depreciation stood at $15.7 million in 2022, then jumped by 55.27% to $24.3 million in 2023, then jumped by 32.66% to $32.3 million in 2024, then increased by 23.67% to $39.9 million in 2025, then advanced by 4.41% to $41.7 million in 2026.
• Business Quant data shows TNYA's Accumulated Depreciation at $41.7 million in Q1 2026, $39.9 million in Q4 2025, and $38.9 million in Q3 2025.